Trends in Mortality from Bone-Metastatic Prostate Cancer in the U.S.

Background

Prostate cancer is a leading cause of cancer-related morbidity and mortality in men, with bone metastasis being a critical factor in disease progression and patient outcomes. Understanding mortality trends associated with bone metastasis is essential. The analysis highlights the importance of multiple-cause-of-death (MCOD) surveillance in capturing the true burden of advanced prostate cancer.

Data Highlights

Key Findings

• The overall AAMR for prostate cancer with bone metastasis rose 93% from 1999 to 2024.
• Non-Hispanic Black men had a mean AAMR 64% higher than non-Hispanic White men.
• Men aged 65–85+ had a 17-fold higher AAMR compared to those aged 45–64.
• Conventional underlying-cause surveillance showed a declining trend, contrasting with MCOD findings.
• The AAMR is projected to reach 3.65 per 100,000 by 2040.

Clinical Implications

The findings emphasize the need for enhanced surveillance and targeted interventions for populations at higher risk of mortality from bone-metastatic prostate cancer. Clinicians should consider the implications of these trends in managing prostate cancer and addressing disparities in care.

Conclusion

The analysis reveals an upward trend in mortality from bone-metastatic prostate cancer.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. Author(s)/Org, Source, Year -- Title
3. Author(s)/Org, Source, Year -- Title
4. Author(s)/Org, Source, Year -- Title
5. Author(s)/Org, Source, Year -- Title
6. Author(s)/Org, Source, Year -- Title
7. Author(s)/Org, Source, Year -- Title
8. Author(s)/Org, Source, Year -- Title
9. Author(s)/Org, Source, Year -- Title
10. Author(s)/Org, Source, Year -- Title
11. Author(s)/Org, Source, Year -- Title
12. Author(s)/Org, Source, Year -- Title
13. Author(s)/Org, Source, Year -- Title
14. Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†
15. https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2025_updated.pdf
16. Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline - PubMed
17. Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology - PubMed
18. FDA expands Pluvicto’s metastatic castration-resistant prostate cancer indication | FDA
19. Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes. | Journal of Clinical Oncology
20. Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer - ScienceDirect
21. Mortality Data Sources | U.S. Cancer Statistics | CDC
22. Multiple Cause of Death 1999-2020